Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medicenna Therapeutics Corp announced that updated clinical data from its Phase 1/2 ABILITY-1 study will be presented at the 2024 Immunotherapy Bridge Conference. The study evaluates MDNA11, an innovative IL-2 super-agonist, in treating advanced solid tumors. This development underscores Medicenna’s commitment to advancing cancer immunotherapies.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.